DR. RUSSELL ROBERT DELUCA M.D. NPI 1114994373

NPI Details

DR. Russell Robert Deluca, M.D. is a hematology and oncology internal medicine in Glen Burnie, MD. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Russell Robert Deluca, M.D. NPI is 1114994373. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

305 HOSPITAL DRIVE
GLEN BURNIE, MD
ZIP 21061
Phone: (410) 761-9896
Fax: (410) 761-2250

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Iron level (HCPCS:83540)
• Ferritin (blood protein) level (HCPCS:82728)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Magnesium level (HCPCS:83735)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Unclassified drugs (HCPCS:J3490)
• Influenza vaccine, quadrivalent derived from cell cultures (HCPCS:90756)
• Telephone medical discussion with physician, 21-30 minutes (HCPCS:99443)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Injection, hydrocortisone sodium succinate, up to 100 mg (HCPCS:J1720)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0220)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)

The enumeration date for this NPI number is 3/7/2006 and was last updated on 2/24/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.